Strongbridge

SBBP NASDAQ
3.230
-0.100
-3.00%
已收盘, 16:00 06/24 EDT
开盘
3.370
昨收
3.330
最高
3.420
最低
2.810
成交量
16.06万
成交均量(3M)
22.46万
52周最高
6.55
52周最低
2.756
换手率
0.30%
市值
1.75亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Strongbridge SBBP股票价格,Strongbridge股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
展开 >

最近浏览

名称
价格
涨跌幅